Search Results - "Foerster, F. G."

Adjuvant treatment strategy and results in small breast cancer tumors (pT1) with HER2 overexpression by Hinke, A., Dall, P., Lenzen, G., Schumacher, C., Rezek, D., Gazawi, N., Ammon, A., Foerster, F. G., Beldermann, F., Cirrincione, U., Wilke, J.

“…Abstract only…”
Get full text

Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC) by Klare, P., Foerster, F. G., Geberth, M., Schneeweiss, A., Tesch, H., Kuemmel, S., Schumacher, C., Hollburg, W., Soeling, U., Schmidt, M.

“…Abstract only…”
Get full text

The clinical significance of triple-negative breast cancer in men (MBC) by Foerster, R., Foerster, F. G., Wulff, V., Schubotz, B., Lange, R., Habeck, J., Baaske, D., Rudlowski, C.

“…Abstract only…”
Get full text

Metastatic male breast cancer (mMBC): Prognosis and survival of 35 patients by Foerster, R., Foerster, F. G., Baaske, D., Schubotz, B., Wulff, V., Rudlowski, C.

“…Abstract only e12001 Background: Only about 1% of breast cancers occur in men, respectively 400–500 new cases per year in Germany. Clinical studies on breast…”
Get full text

Expectations of palliative patients (pts) by Foerster, F. G., Szczesny, J., Brandt, G.

“…Abstract only…”
Get full text

Symptom control during the terminal phase of malignancies by Foerster, F. G., Moebius, E., Wagner, I., Schlegel, E.

“…Abstract only…”
Get full text

Symptom control during the terminal phase of malignancies by Foerster, F. G., Moebius, E., Wagner, I., Schlegel, E.

“…Abstract only…”
Get full text

P1-14-04: Prolonged (≥1 Year) Exposure to First-Line Bevacizumab Combined with Paclitaxel in Patients with HER2−Negative Metastatic Breast Cancer Treated in a Routine Oncology Practice Study by Kuemmel, S, Schneeweiss, A, Foerster, FG, Geberth, M, Tesch, H, Klare, P, Schumacher, C, Hollburg, W, Soeling, U, Schmidt, M

“…Abstract Background: First-line bevacizumab (BEV) combined with weekly paclitaxel (PAC) significantly improves progression-free survival (PFS) and response…”
Get full text

Abstract P2-16-12: First-Line Bevacizumab Combined with Paclitaxel in Triple-Negative Locally Recurrent/Metastatic Breast Cancer: Subpopulation Analysis of 115 Patients Treated in Routine Oncology Practice in Germany by Schneeweiss, A, Foerster, FG, Hollburg, W, Tesch, H, Klare, P, Wuelfing, P, Distelrath, A, Schumacher, C, Steffens, C-C, Schubert, R, Widing, A, Kasper, C, Schmidt, M.

“…Abstract Background: Both progression-free survival (PFS) and response rate (RR) are significantly improved when bevacizumab (Bev) is combined with first-line…”
Get full text

Matched-pair analysis of female and male breast cancer: a comprehensive cohort study by Foerster, R, Foerster, FG, Wulff, V, Schubotz, B, Lange, R, Habeck, J, Baaske, D, Rudlowski, C

“…Abstract Abstract #4129 Introduction:
 Male breast cancer (MBC) is a rare disease accounting for approximately 1% of all breast carcinomas. Due to the low…”
Get full text